Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study

“…Clinical characteristics, treatment protocols, and clinical outcome of NHL survivors have been recently published [17]; those of HL survivors are under submission for publication in another journal. Demographic characteristics, follow-up time since treatment initiation and medical history as reported by survivors were described using numbers and proportions for HL and NHL separately.…”

“…Variables included in the models were age at the time of survivorship assessment, follow-up time, gender, education level, cohabitation status, obesity and presence of health disorders at fatigue assessment. Primary treatments (including autologous stem-cell transplantation administered upfront in NHL patients) were not included in the models because they did not influence long-term fatigue levels as previously shown [2, 3, 14, 17]. Salvage treatments delivered for a relapse were not considered as well for the same reason.…”

“…For age and follow-up time since treatment initiation the regression coefficient β estimates the change in score associated with a 10-year increase. Cases aged ≥70 years (10% of the population) were grouped because in a previous study focusing on NHL it was shown that fatigue level remained unchanged until 69 years of age and significantly increased beyond [17]. A score can be estimated by simply adding the following terms: intercept + (β age < 70 x (age-20)/10) + β age ≥ 70 + (β follow-up x follow-up time/10) + β i V i (where V i represents any covariate included in the model and β i its regression coefficient).…”

“…Survival improvement in HL brought physicians’ attention to persistent fatigue that was observed in a substantial proportion of survivors, including those who survived childhood HL, which might exceed 65% [2, 16]. In two series of lymphoma survivors enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Lymphoma Study Association (LYSA) clinical trials, the proportions of individuals who reported long-term fatigue were 64 and 62% in HL and NHL survivors, respectively [2, 17]. Factors generally associated with increased prevalence of fatigue or increased fatigue level were age, female gender, low education level, and presence of health disorders.…”

Najważniejsze doniesienia dotyczące nowotworów układu chłonnego z dorocznej konferencji Amerykańskiego Towarzystwa Onkologii Klinicznej w 2016 roku

“…Niezwykle wartościową analizę przedstawili Mounier i wsp. w badaniu Simonal (streszczenie 7518) [11] służącym ocenie późnej toksyczności leczenia chorych na chłoniaki nie-Hodgkina (NHL, non-Hodgkin lymphoma) na podstawie analizy 12 badań francuskiej grupy LYSA (Collaborative Lymphoma Study Association). Powszechnie wiadomo, że chorzy po leczeniu z powodu NHL są obarczeni podwyższonym ryzykiem rozwoju nowotworów wtórnych i późnej toksyczności, obejmującej przede wszystkim choroby układu sercowo-naczyniowego i neuropsychiatryczne.…”